

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9989)**

**CHANGE OF JOINT COMPANY SECRETARY AND  
AUTHORIZED REPRESENTATIVE  
AND  
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28  
AND 8.17 OF THE LISTING RULES**

The Board announces that (i) Mr. Bu has resigned from his positions as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020; (ii) Ms. Tan has been appointed as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020; and (iii) the Company has applied to the Stock Exchange and has been granted a waiver by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules.

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that Mr. Bu Haihua (“**Mr. Bu**”) resigned as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); and (ii) an authorized representative (the “**Authorized Representative**”) under the Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) with effect from September 18, 2020, in order to pursue other business and work commitments.

Mr. Bu has confirmed that he has no disagreement with the Board and that there is no other matters in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Ms. Tan Xuan (“**Ms. Tan**”) has been appointed as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020.

The biographical details of Ms. Tan are set out as follows:

Ms. Tan Xuan ( 談煊 ), born in 1982, holds a bachelor's degree in economics and a master's degree in finance from Renmin University of China. Ms. Tan has been engaged in capital market industry and company research for a long time, participated in the completion of many mergers and acquisitions, and has rich experience in industry analysis and mergers and acquisitions. Ms. Tan has been the director of the Office of secretary to the Board of the Company since June 2020. From April 2007 to November 2014, Ms. Tan successively worked at Harvest Fund Management Co., Ltd., Economy Research Institute of Geosen Securities Co., Ltd. ( 國信證券股份有限公司經濟研究所 ) and Securities Research Institute of Shenyn & Wanguo Securities Co., Ltd. ( 申銀萬國股份有限公司證券研究所 ), and won many awards such as the Best Analyst of New Fortune; from November 2014 to May 2020, she worked at Geo-Jade Petroleum Corporation (a company listed in the Shanghai Stock Exchange, stock code: 600759), and was appointed as the secretary to the board of directors of Geo-Jade Petroleum Corporation in 2017 and vice president in 2019.

Ms. Tan has obtained the board secretary certificate for a listed company which is required for qualification. Currently, she does not hold any shares of the Company, has no relationship with shareholders holding more than 5% of the shares of the Company, Directors, Supervisors, or senior management personnel of the Company, and has not been subject to any disciplinary action by the China Securities Regulatory Commission and other relevant departments and the punishment of exchanges.

Having considered Ms. Tan's background and experience, the Board is of the view that, although Ms. Tan is yet to possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules, she is capable of discharging her functions as a Joint Company Secretary. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Ms. Tan to act as a Joint Company Secretary (the "**Waiver**") for a period of three years from the date of such appointment, being September 18, 2020 (the "**Waiver Period**").

The granting of the Waiver is conditional upon that (i) Ms. Tan will be assisted by Ms. Chan Sze Ting ("**Ms. Chan**"), the other Joint Company Secretary, to acquire the relevant experience and discharge her functions as a Joint Company Secretary during the Waiver Period; (ii) the Company shall notify the Stock Exchange at the end of the Waiver Period to re-visit the situation. The Company expects to demonstrate that Ms. Tan can satisfy Rules 3.28 and 8.17 of the Listing Rules at the end of the Waiver Period, having had the benefit of Ms. Chan's assistance such that a further Waiver would not be necessary; and (iii) the Company will announce details of the Waiver, including the reasons and conditions. The Waiver will be revoked immediately if and when Ms. Chan ceases to provide assistance to Ms. Tan. The Stock Exchange may withdraw or change the Waiver if the situation of the Company changes.

The biographical details of Ms. Chan are set out as follows:

Ms. Chan Sze Ting ( 陳詩婷 ) is the joint company secretary of the Company. Ms. Chan currently serves as a senior manager of corporate services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. Ms. Chan has over 14 years of experience in the corporate secretarial field. She has been providing professional corporate services to multiple Hong Kong listed companies. Ms. Chan is currently the joint company secretary of Sinopec Shanghai Petrochemical Company Limited (a company listed on the Main Board of the Stock Exchange, stock code: 338 and listed on the Shanghai Stock Exchange, stock code: 600688), the company secretary of Sunfonda Group Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1771), Modern Media Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 72), Century Sage Scientific Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1450) and Vico International Holdings Limited (a company listed on the Main Board of the Hong Kong Stock Exchange, stock code: 1621). Ms. Chan is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute in the United Kingdom. Ms. Chan holds a bachelor of laws degree from the University of London.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Bu for his valuable contributions to the Company during his tenure of service and extend its warm welcome to Ms. Tan on her new appointment.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
September 18, 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*